General Information of Drug (ID: DM9IPH4)

Drug Name
CMPD-167 Drug Info
Synonyms
L-167; MRK-167; CCR5 inhibitor (HIV infection), IPM; CCR5 inhibitor (vaginal formulation), IPM; CMPD-167 (HIV infection); CMPD-167 (HIV infection), IPM; CMPD-167 (HIV infection), International Partnership for Microbiocides
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus-1 infection 1C62 Investigative [1]
Cross-matching ID
PubChem CID
5481119
CAS Number
CAS 313994-79-5
TTD Drug ID
DM9IPH4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Maraviroc DMTL94F Human immunodeficiency virus infection 1C62 Approved [3]
Vicriviroc DMMTW9K Human immunodeficiency virus infection 1C62 Phase 3 [4]
PRO-140 DMD1FTP Human immunodeficiency virus infection 1C62 Phase 3 [5]
E-913 DMUHS5Q Human immunodeficiency virus infection 1C62 Phase 3 [6]
PRO 140 DMCGK6X Human immunodeficiency virus-1 infection 1C62 Phase 2/3 [7]
INCB9471 DMMWC6F Infectious disease 1A00-CA43.1 Phase 2a [6]
Cenicriviroc DM4V8WF Human immunodeficiency virus infection 1C62 Phase 2 [8]
BMS-813160 DMKY638 Diabetic nephropathy GB61.Z Phase 2 [9]
SB-728-T DMRWE5D Human immunodeficiency virus infection 1C62 Phase 2 [10]
PF-232798 DM8T6KQ Human immunodeficiency virus infection 1C62 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-C chemokine receptor type 5 (CCR5) TT2CEJG CCR5_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3651).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3651).
3 Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9.
4 HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42.
5 Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62.
6 Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34.
7 The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353.
8 The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6.
9 A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24.
10 Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910.
11 An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77.